June 6, 2023 – Boston, Massachusetts. WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and T-MAXIMUM today signed a strategic collaboration agreement. WuXi ATU will provide integrated testing,...
Wednesday March 8, 2023 – TICAROS, a Korean CAR-T developing biotech in partnership with WuXi Advanced Therapies (WuXi ATU) received IND approval from the Korean Ministry of Food and Drug Safety (MFDS). WuXi Advanced Therapies is a global Contract Testing, Development...
August 11, 2022 – PHILADELPHIA, PA. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under...
January 07, 2022 – Philadelphia. WuXi Advanced Therapies (WuXi ATU) announced it has successfully completed a remote European Medicines Agency (EMA) inspection for its advanced therapies testing facility at 400 Rouse Boulevard in its Philadelphia Navy Yard Campus, and...
